Addressing protein aggregation, product stability, supply chains, and regulations requires multiple tools, including ...

CEO Dr Katie King said that the microgravity environment enables the production of purer crystals, resulting in more ...

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company redefining the treatment of autoimmune and ...

Certain botulinum toxin type A formulations may offer a faster onset of efficacy, whereas others maintain results for a ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the ...

DelveInsight's, “Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ ...

Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of pediatric patients aged 6 to 17 years with ADHD.

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA ® (zanubrutinib) ...

New formulation provides patients with a simplified dosing experience-reducing pill burden and enhancing ease of administration-while preserving flexible dosing options BeOne Medicines Ltd. (NASDAQ: ...